Does Rallies show Form 4 insider transactions for MNPR?

Yes. Rallies tracks MNPR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MNPR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MNPR. It does not provide personalized investment advice.

MNPR (Monopar Therapeutics Inc. Common Stock) Stock Analysis - Insider Trades

Monopar Therapeutics Inc. Common Stock (MNPR) is a publicly traded Healthcare sector company. As of May 20, 2026, MNPR trades at $57.95 with a market cap of $376.82M and a P/E ratio of -29.81. MNPR moved -1.64% today. Year to date, MNPR is -16.38%; over the trailing twelve months it is +49.59%. Its 52-week range spans $4.50 to $105.00. Analyst consensus is strong buy with an average price target of $113.00. Rallies surfaces MNPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MNPR stock inside the company?

Recent MNPR insider activity includes Vu Quan Anh bought 1.50K, KLAUSNER ARTHUR J sold 4.66K, KLAUSNER ARTHUR J sold 461, Tactic Pharma LLC sold 550.23K, and Tsuchimoto Kim R sold 8.90K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MNPR Key Metrics

Key financial metrics for MNPR
Metric	Value
Price	$57.95
Market Cap	$376.82M
P/E Ratio	-29.81
EPS	$-1.85
Dividend Yield	0.00%
52-Week High	$105.00
52-Week Low	$4.50
Volume	235.59K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-13.72M
Gross Margin	0.00%

Recent MNPR Insider Trades

Vu Quan Anh bought 1.50K (~$104.92K) on Dec 26, 2025.
KLAUSNER ARTHUR J sold 4.66K (~$312.50K) on Dec 18, 2025.
KLAUSNER ARTHUR J sold 461 (~$31.39K) on Dec 18, 2025.
Tactic Pharma LLC sold 550.23K (~$35.00M) on Sep 24, 2025.
Tsuchimoto Kim R sold 8.90K (~$356.17K) on Jul 14, 2025.

Latest MNPR News

ALXN1840 Phase 2 Trial in Nine Patients Cuts Copper Balance 6.08 mg, Boosts Fecal Excretion 50% — May 19, 2026
Monopar Therapeutics Holds $137.5M Cash, Phase 3 ALXN1840 NDA Submission On Track — May 14, 2026
Monopar’s ALXN1840 Cuts Neurologic Worsening to 9% vs 25% at Week 48 — Apr 19, 2026
Monopar Appoints Susan Rodriguez Chief Commercial and Strategy Officer for H1 2026 NDA — Mar 2, 2026

MNPR Analyst Consensus

7 analysts cover MNPR: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $113.00.

Common questions about MNPR

Who is trading MNPR stock inside the company?: Recent MNPR insider activity includes Vu Quan Anh bought 1.50K, KLAUSNER ARTHUR J sold 4.66K, KLAUSNER ARTHUR J sold 461, Tactic Pharma LLC sold 550.23K, and Tsuchimoto Kim R sold 8.90K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MNPR?: Yes. Rallies tracks MNPR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MNPR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MNPR. It does not provide personalized investment advice.